Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Appears To Have Avoided Shutdown-Related ANDA Bolus

Executive Summary

Generic submissions were below historical norms in December and modestly higher January, meaning shutdown likely did not create a large pile of pending work.

You may also be interested in...



US FDA Inspection Goals Reduced After Shutdown; Review Dates Look Safe

Commissioner Gottlieb tells Congress that FDA won’t meet all its planned goals for inspections after month-long partial government shutdown, but he does not expect a noticeable impact on product reviews. The longer term impact will depend on morale: hiring and retention are key focus. 

FDA's Post-Shutdown ANDA Bolus Could Be Massive

More than 300 generic drug applications might be officially filed when the shutdown ends, substantially increasing stress on assessors and other Office of Generic Drugs staff.

Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases

ANDA and NDA/BLA supplement approvals continue thanks to carryover user fee funds, but US FDA hasn't made any NDA and BLA approvals during shutdown as as anxiety over effect of "lapse period" on agency increases.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel